The introduction of the 750mcg parathyroid hormone product in Australia has seen cautious sales . Currently, this increased dose injection is largely intended for patients with significant osteoporosis who have been unsuccessful with other treatments . Procurement can be challenging due to specialist approval requirements and restricted pharmacy ch